Judge reverses jury decision over $6.5m Takeda payout


A judge has thrown out the jury’s verdict in a case between Japanese drugmaker Takeda and a US man who claims that the company’s drug caused his bladder cancer.

On 29 April, a jury decided in favour of Jack Cooper, saying that the company didn’t do enough to warn him that Actos (pioglitazone) would increase his risk of bladder cancer. The company was ordered to pay Cooper $6.5 million (£4.2 million) in damages.

However, Takeda appealed to the judge, claiming that there was not enough evidence to directly link Cooper’s cancer to the drug. The judge agreed and nullified the jury’s decision.

The case is the first of over 3300 that have been compiled against the company over bladder cancer claims. In 2011, after reviewing safety data on pioglitazone, the US Food and Drugs Administration (FDA) highlighted a possible but unproven link between the drug and increased risk of bladder cancer. The FDA recommended it not be prescribed to patients with active bladder cancer or history of the disease.

Takeda maintains that it has acted responsibly regarding the safety of Actos, disclosing safety data to regulatory authorities and warning about other side effects, such as heart problems.


Related Content

Missing safety risk emails draw $9bn Actos fine

11 April 2014 Business

news image

Judge finds absence of Takeda documentation in bladder cancer case ‘disturbing’

Judge slashes fines in drug safety case

29 October 2014 Business

news image

Takeda and Eli Lilly’s $9 billion damages in diabetes trial reduced to $38 million

Most Read

Sun rises on new solar route to hydrogen

27 February 2015 Research

news image

Photocatalyst has solar-to-hydrogen conversion efficiency of 2% and points way to cheap production of the gas

Shedding light on fading reds in Van Gogh’s paintings

3 March 2015 Research

news image

An exotic lead mineral may be the ‘missing link’ in explaining why the Dutch artist’s work has lost its colour

Most Commented

Sun rises on new solar route to hydrogen

27 February 2015 Research

news image

Photocatalyst has solar-to-hydrogen conversion efficiency of 2% and points way to cheap production of the gas

Hepatitis C drug patent challenged in Europe

19 February 2015 Business

news image

Campaign group says Gilead’s expensive blockbuster sofosbuvir is not innovative enough to warrant a patent